search
Back to results

Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction

Primary Purpose

Chronic Heart Failure With Reduced Ejection Fraction

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
LCZ696
Sponsored by
Novartis Pharmaceuticals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Heart Failure With Reduced Ejection Fraction focused on measuring LCZ696, chronic heart failure, ARNI, Congestive heart failure (CHF), heart failure (HF), acute heart failure syndrome, congestive cardiac failure (CCF)

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Written informed consent for the extension must be obtained before any assessment is performed.
  2. Patients who have completed PARADIGM-HF (protocol CLCZ696B2314) and are able to be safely enrolled into the open-label trial as judged by the investigator.

Exclusion Criteria:

  1. Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer
  2. History of hypersensitivity or allergy to any of the study drugs, drugs of similar chemical classes, ACEIs, ARBs, or NEP inhibitors as well as known or suspected contraindications to LCZ696
  3. Known history of angioedema
  4. Requirement of simultaneous treatment with both ACEIs and ARBs
  5. Current acute decompensated HF (exacerbation of chronic HF manifested by signs and symptoms that may require intravenous therapy)
  6. Symptomatic hypotension and/or a SBP < 100 mmHg at Visit 1 (screening)
  7. Estimated GFR < 30 mL/min/1.73m^2 as measured by the simplified MDRD formula at Visit 1 (screening)
  8. Presence of bilateral renal artery stenosis
  9. Serum potassium > 5.2 mmol/L at Visit 1 (screening)
  10. Evidence of hepatic disease as determined by any one of the following: AST or ALT values exceeding 3 x ULN at Visit 1, history of hepatic encephalopathy, history of esophageal varices, or history of portacaval shunt
  11. Pregnant or nursing (lactating) women
  12. Women of child-bearing potential
  13. Any condition, not identified in the protocol, that in the opinion of the investigator is likely to prevent the patient from safely tolerating LCZ696 or complying with the requirements of the study.

Sites / Locations

  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

LCZ696

Arm Description

Angiotensin receptor antagonist neprilysin inhibitor (ARNI) with target dose of 200 mg bid

Outcomes

Primary Outcome Measures

Percentage of Participants With Treatment Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths as a Measure of Safety and Tolerability of LCZ696
The primary assessments for safety were the reporting of angioedema, AEs suspected to be related to LCZ696, AEs leading to study drug discontinuation and serious adverse events (SAE) including death. The assessment of safety were based primarily on the frequency of adverse events of special interest, sitting systolic and diastolic blood pressure, heart rate, and serious adverse events suspected by the investigators to be related to LCZ696 for the Safety set. Only descriptive analysis done.

Secondary Outcome Measures

Full Information

First Posted
August 25, 2014
Last Updated
February 19, 2019
Sponsor
Novartis Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT02226120
Brief Title
Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction
Official Title
A Multicenter Study to Evaluate Safety and Tolerability in Patients With Chronic Heart Failure and Reduced Ejection Fraction From PARADIGM-HF Receiving Open Label LCZ696
Study Type
Interventional

2. Study Status

Record Verification Date
February 2019
Overall Recruitment Status
Completed
Study Start Date
October 16, 2014 (Actual)
Primary Completion Date
December 28, 2017 (Actual)
Study Completion Date
December 28, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novartis Pharmaceuticals

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study was to collect safety and tolerability data on LCZ696 in eligible PARADIGM-HF patients who received open-label investigational drug. The parent PARADIGM-HF (NCT01035255) trial was terminated early due to compelling efficacy of LCZ696 in patients with heart failure with reduced ejection fraction (HFrEF) after the final pre-specified interim analysis in March 2014.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Heart Failure With Reduced Ejection Fraction
Keywords
LCZ696, chronic heart failure, ARNI, Congestive heart failure (CHF), heart failure (HF), acute heart failure syndrome, congestive cardiac failure (CCF)

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
1980 (Actual)

8. Arms, Groups, and Interventions

Arm Title
LCZ696
Arm Type
Experimental
Arm Description
Angiotensin receptor antagonist neprilysin inhibitor (ARNI) with target dose of 200 mg bid
Intervention Type
Drug
Intervention Name(s)
LCZ696
Intervention Description
Angiotensin receptor antagonist neprilysin inhibitor (ARNI) with target dose of 200 mg bid
Primary Outcome Measure Information:
Title
Percentage of Participants With Treatment Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths as a Measure of Safety and Tolerability of LCZ696
Description
The primary assessments for safety were the reporting of angioedema, AEs suspected to be related to LCZ696, AEs leading to study drug discontinuation and serious adverse events (SAE) including death. The assessment of safety were based primarily on the frequency of adverse events of special interest, sitting systolic and diastolic blood pressure, heart rate, and serious adverse events suspected by the investigators to be related to LCZ696 for the Safety set. Only descriptive analysis done.
Time Frame
From first dose of study treatment to 30 days after last dose of study treatment, up to 30 months.

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Written informed consent for the extension must be obtained before any assessment is performed. Patients who have completed PARADIGM-HF (protocol CLCZ696B2314) and are able to be safely enrolled into the open-label trial as judged by the investigator. Exclusion Criteria: Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer History of hypersensitivity or allergy to any of the study drugs, drugs of similar chemical classes, ACEIs, ARBs, or NEP inhibitors as well as known or suspected contraindications to LCZ696 Known history of angioedema Requirement of simultaneous treatment with both ACEIs and ARBs Current acute decompensated HF (exacerbation of chronic HF manifested by signs and symptoms that may require intravenous therapy) Symptomatic hypotension and/or a SBP < 100 mmHg at Visit 1 (screening) Estimated GFR < 30 mL/min/1.73m^2 as measured by the simplified MDRD formula at Visit 1 (screening) Presence of bilateral renal artery stenosis Serum potassium > 5.2 mmol/L at Visit 1 (screening) Evidence of hepatic disease as determined by any one of the following: AST or ALT values exceeding 3 x ULN at Visit 1, history of hepatic encephalopathy, history of esophageal varices, or history of portacaval shunt Pregnant or nursing (lactating) women Women of child-bearing potential Any condition, not identified in the protocol, that in the opinion of the investigator is likely to prevent the patient from safely tolerating LCZ696 or complying with the requirements of the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Novartis Pharmaceuticals
Organizational Affiliation
Novartis Pharmaceuticals
Official's Role
Study Director
Facility Information:
Facility Name
Novartis Investigative Site
City
Huntsville
State/Province
Alabama
ZIP/Postal Code
35801
Country
United States
Facility Name
Novartis Investigative Site
City
Muscle Shoals
State/Province
Alabama
ZIP/Postal Code
35662
Country
United States
Facility Name
Novartis Investigative Site
City
Little Rock
State/Province
Arkansas
ZIP/Postal Code
72204
Country
United States
Facility Name
Novartis Investigative Site
City
Oceanside
State/Province
California
ZIP/Postal Code
92056
Country
United States
Facility Name
Novartis Investigative Site
City
Palm Springs
State/Province
California
ZIP/Postal Code
92262
Country
United States
Facility Name
Novartis Investigative Site
City
San Diego
State/Province
California
ZIP/Postal Code
92161
Country
United States
Facility Name
Novartis Investigative Site
City
Santa Rosa
State/Province
California
ZIP/Postal Code
95405
Country
United States
Facility Name
Novartis Investigative Site
City
Boynton Beach
State/Province
Florida
ZIP/Postal Code
33472-2952
Country
United States
Facility Name
Novartis Investigative Site
City
Des Moines
State/Province
Iowa
ZIP/Postal Code
50314
Country
United States
Facility Name
Novartis Investigative Site
City
Covington
State/Province
Louisiana
ZIP/Postal Code
70433
Country
United States
Facility Name
Novartis Investigative Site
City
Columbia
State/Province
Maryland
ZIP/Postal Code
21044
Country
United States
Facility Name
Novartis Investigative Site
City
Saginaw
State/Province
Michigan
ZIP/Postal Code
48601
Country
United States
Facility Name
Novartis Investigative Site
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55417
Country
United States
Facility Name
Novartis Investigative Site
City
Fremont
State/Province
Nebraska
ZIP/Postal Code
68025
Country
United States
Facility Name
Novartis Investigative Site
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
Facility Name
Novartis Investigative Site
City
Rosedale
State/Province
New York
ZIP/Postal Code
11422
Country
United States
Facility Name
Novartis Investigative Site
City
Raleigh
State/Province
North Carolina
ZIP/Postal Code
27610
Country
United States
Facility Name
Novartis Investigative Site
City
Marion
State/Province
Ohio
ZIP/Postal Code
43302
Country
United States
Facility Name
Novartis Investigative Site
City
Rapid City
State/Province
South Dakota
ZIP/Postal Code
57701
Country
United States
Facility Name
Novartis Investigative Site
City
Dallas
State/Province
Texas
ZIP/Postal Code
75235
Country
United States
Facility Name
Novartis Investigative Site
City
Dallas
State/Province
Texas
ZIP/Postal Code
75251
Country
United States
Facility Name
Novartis Investigative Site
City
Livingston
State/Province
Texas
ZIP/Postal Code
77351
Country
United States
Facility Name
Novartis Investigative Site
City
Spokane
State/Province
Washington
ZIP/Postal Code
99204
Country
United States
Facility Name
Novartis Investigative Site
City
Waukesha
State/Province
Wisconsin
ZIP/Postal Code
53188
Country
United States
Facility Name
Novartis Investigative Site
City
Caba
State/Province
Buenos Aires
ZIP/Postal Code
C1221ADC
Country
Argentina
Facility Name
Novartis Investigative Site
City
Ciudad Autonoma de Bs As
State/Province
Buenos Aires
ZIP/Postal Code
C1119ACN
Country
Argentina
Facility Name
Novartis Investigative Site
City
Mar del Plata
State/Province
Buenos Aires
ZIP/Postal Code
B7600FZN
Country
Argentina
Facility Name
Novartis Investigative Site
City
Quilmes
State/Province
Buenos Aires
ZIP/Postal Code
B1878DVB
Country
Argentina
Facility Name
Novartis Investigative Site
City
Caba
State/Province
Capital Federal
ZIP/Postal Code
C1179AAB
Country
Argentina
Facility Name
Novartis Investigative Site
City
San Salvador de Jujuy
State/Province
Jujuy
ZIP/Postal Code
Y4600ABF
Country
Argentina
Facility Name
Novartis Investigative Site
City
Ciudad de Salta
State/Province
Provincia De Salta
ZIP/Postal Code
A4406BPF
Country
Argentina
Facility Name
Novartis Investigative Site
City
Rosario
State/Province
Santa Fe
ZIP/Postal Code
2000
Country
Argentina
Facility Name
Novartis Investigative Site
City
Rosario
State/Province
Santa Fe
ZIP/Postal Code
S2000AII
Country
Argentina
Facility Name
Novartis Investigative Site
City
Rosario
State/Province
Santa Fe
ZIP/Postal Code
S2000QID
Country
Argentina
Facility Name
Novartis Investigative Site
City
Cordoba
ZIP/Postal Code
5000
Country
Argentina
Facility Name
Novartis Investigative Site
City
Cordoba
ZIP/Postal Code
X5000AAX
Country
Argentina
Facility Name
Novartis Investigative Site
City
Cordoba
ZIP/Postal Code
X5016KET
Country
Argentina
Facility Name
Novartis Investigative Site
City
Corrientes
ZIP/Postal Code
W3400CLH
Country
Argentina
Facility Name
Novartis Investigative Site
City
Formosa
ZIP/Postal Code
P3600
Country
Argentina
Facility Name
Novartis Investigative Site
City
Formosa
ZIP/Postal Code
P3634XAR
Country
Argentina
Facility Name
Novartis Investigative Site
City
Mendoza
ZIP/Postal Code
M5500CHC
Country
Argentina
Facility Name
Novartis Investigative Site
City
San Luis
ZIP/Postal Code
D5702JRS
Country
Argentina
Facility Name
Novartis Investigative Site
City
Santa Fe
ZIP/Postal Code
S3000EOZ
Country
Argentina
Facility Name
Novartis Investigative Site
City
Santa Fe
ZIP/Postal Code
S3000FWO
Country
Argentina
Facility Name
Novartis Investigative Site
City
Santiago del Estero
ZIP/Postal Code
G4200AQK
Country
Argentina
Facility Name
Novartis Investigative Site
City
Brasschaat
ZIP/Postal Code
2930
Country
Belgium
Facility Name
Novartis Investigative Site
City
Gent
ZIP/Postal Code
9000
Country
Belgium
Facility Name
Novartis Investigative Site
City
La Louviere
ZIP/Postal Code
7100
Country
Belgium
Facility Name
Novartis Investigative Site
City
Leuven
ZIP/Postal Code
3000
Country
Belgium
Facility Name
Novartis Investigative Site
City
Ronse
ZIP/Postal Code
9600
Country
Belgium
Facility Name
Novartis Investigative Site
City
Salvador
State/Province
BA
ZIP/Postal Code
41810-010
Country
Brazil
Facility Name
Novartis Investigative Site
City
Brasilia
State/Province
DF
ZIP/Postal Code
70390-903
Country
Brazil
Facility Name
Novartis Investigative Site
City
Goiania
State/Province
GO
ZIP/Postal Code
74223-130
Country
Brazil
Facility Name
Novartis Investigative Site
City
Goiania
State/Province
GO
ZIP/Postal Code
74605 050
Country
Brazil
Facility Name
Novartis Investigative Site
City
Goiania
State/Province
GO
ZIP/Postal Code
74823-470
Country
Brazil
Facility Name
Novartis Investigative Site
City
Sao Luis
State/Province
MA
ZIP/Postal Code
65020-070
Country
Brazil
Facility Name
Novartis Investigative Site
City
Uberlandia
State/Province
Mg-cep
ZIP/Postal Code
38411-186
Country
Brazil
Facility Name
Novartis Investigative Site
City
Belo Horizonte
State/Province
MG
ZIP/Postal Code
20180-090
Country
Brazil
Facility Name
Novartis Investigative Site
City
Belo Horizonte
State/Province
MG
ZIP/Postal Code
30150-221
Country
Brazil
Facility Name
Novartis Investigative Site
City
Belem
State/Province
PA
ZIP/Postal Code
66087-660
Country
Brazil
Facility Name
Novartis Investigative Site
City
Recife
State/Province
PE
ZIP/Postal Code
52051-380
Country
Brazil
Facility Name
Novartis Investigative Site
City
Rio de Janeiro
State/Province
RJ
ZIP/Postal Code
22280-020
Country
Brazil
Facility Name
Novartis Investigative Site
City
Porto Alegre
State/Province
RS
ZIP/Postal Code
90880-480
Country
Brazil
Facility Name
Novartis Investigative Site
City
Marilia
State/Province
SP
ZIP/Postal Code
17515-000
Country
Brazil
Facility Name
Novartis Investigative Site
City
Ribeirao Preto
State/Province
SP
ZIP/Postal Code
14055-370
Country
Brazil
Facility Name
Novartis Investigative Site
City
Santo Andre
State/Province
SP
ZIP/Postal Code
09190-615
Country
Brazil
Facility Name
Novartis Investigative Site
City
Sao Jose do Rio Preto
State/Province
SP
ZIP/Postal Code
15015-750
Country
Brazil
Facility Name
Novartis Investigative Site
City
Sao Paulo
State/Province
SP
ZIP/Postal Code
01323 000
Country
Brazil
Facility Name
Novartis Investigative Site
City
Sao Paulo
State/Province
SP
ZIP/Postal Code
05403-000
Country
Brazil
Facility Name
Novartis Investigative Site
City
Votuporanga
State/Province
SP
ZIP/Postal Code
15500-003
Country
Brazil
Facility Name
Novartis Investigative Site
City
Haskovo
ZIP/Postal Code
6300
Country
Bulgaria
Facility Name
Novartis Investigative Site
City
Pleven
ZIP/Postal Code
5800
Country
Bulgaria
Facility Name
Novartis Investigative Site
City
Plovdiv
ZIP/Postal Code
4000
Country
Bulgaria
Facility Name
Novartis Investigative Site
City
Shumen
ZIP/Postal Code
9700
Country
Bulgaria
Facility Name
Novartis Investigative Site
City
Sofia
ZIP/Postal Code
1233
Country
Bulgaria
Facility Name
Novartis Investigative Site
City
Sofia
ZIP/Postal Code
1309
Country
Bulgaria
Facility Name
Novartis Investigative Site
City
Sofia
ZIP/Postal Code
1431
Country
Bulgaria
Facility Name
Novartis Investigative Site
City
Sofia
ZIP/Postal Code
1527
Country
Bulgaria
Facility Name
Novartis Investigative Site
City
Sofia
ZIP/Postal Code
1606
Country
Bulgaria
Facility Name
Novartis Investigative Site
City
Varna
ZIP/Postal Code
9010
Country
Bulgaria
Facility Name
Novartis Investigative Site
City
Victoria
State/Province
British Columbia
ZIP/Postal Code
V8R4R2
Country
Canada
Facility Name
Novartis Investigative Site
City
Halifax
State/Province
Nova Scotia
ZIP/Postal Code
B3H 2Y9
Country
Canada
Facility Name
Novartis Investigative Site
City
Kitchener
State/Province
Ontario
ZIP/Postal Code
N2M 5N4
Country
Canada
Facility Name
Novartis Investigative Site
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5B 1W8
Country
Canada
Facility Name
Novartis Investigative Site
City
Weston
State/Province
Ontario
ZIP/Postal Code
M9N 1W4
Country
Canada
Facility Name
Novartis Investigative Site
City
Levis
State/Province
Quebec
ZIP/Postal Code
G6V 4Z5
Country
Canada
Facility Name
Novartis Investigative Site
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H3G 1A4
Country
Canada
Facility Name
Novartis Investigative Site
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H3T 1E2
Country
Canada
Facility Name
Novartis Investigative Site
City
St-Georges Beauce
State/Province
Quebec
ZIP/Postal Code
G5Y 4T8
Country
Canada
Facility Name
Novartis Investigative Site
City
Temuco
State/Province
Araucania
ZIP/Postal Code
4780000
Country
Chile
Facility Name
Novartis Investigative Site
City
Beroun
State/Province
Czech Republic
ZIP/Postal Code
266 01
Country
Czechia
Facility Name
Novartis Investigative Site
City
Brandys nad Labem
State/Province
Czech Republic
ZIP/Postal Code
250 01
Country
Czechia
Facility Name
Novartis Investigative Site
City
Liberec V Kristianova
State/Province
Czech Republic
ZIP/Postal Code
460 05
Country
Czechia
Facility Name
Novartis Investigative Site
City
Olomouc
State/Province
Czech Republic
ZIP/Postal Code
779 00
Country
Czechia
Facility Name
Novartis Investigative Site
City
Prague 10, Vrsovice
State/Province
Czech Republic
ZIP/Postal Code
10100
Country
Czechia
Facility Name
Novartis Investigative Site
City
Trebic
State/Province
Czech Republic
ZIP/Postal Code
674 01
Country
Czechia
Facility Name
Novartis Investigative Site
City
Bilovec
State/Province
CZE
ZIP/Postal Code
743 01
Country
Czechia
Facility Name
Novartis Investigative Site
City
Kolin
ZIP/Postal Code
280 20
Country
Czechia
Facility Name
Novartis Investigative Site
City
Prague 5
ZIP/Postal Code
150 30
Country
Czechia
Facility Name
Novartis Investigative Site
City
Praha
ZIP/Postal Code
12808
Country
Czechia
Facility Name
Novartis Investigative Site
City
Uherske Hradiste
ZIP/Postal Code
68601
Country
Czechia
Facility Name
Novartis Investigative Site
City
Copenhagen
ZIP/Postal Code
DK-2100
Country
Denmark
Facility Name
Novartis Investigative Site
City
Esbjerg
ZIP/Postal Code
DK-6700
Country
Denmark
Facility Name
Novartis Investigative Site
City
Hellerup
ZIP/Postal Code
DK-2900
Country
Denmark
Facility Name
Novartis Investigative Site
City
Randers
ZIP/Postal Code
8930
Country
Denmark
Facility Name
Novartis Investigative Site
City
Svendborg
ZIP/Postal Code
5700
Country
Denmark
Facility Name
Novartis Investigative Site
City
Vejle
ZIP/Postal Code
7100
Country
Denmark
Facility Name
Novartis Investigative Site
City
Viborg
ZIP/Postal Code
DK-8800
Country
Denmark
Facility Name
Novartis Investigative Site
City
Tallinn
ZIP/Postal Code
13419
Country
Estonia
Facility Name
Novartis Investigative Site
City
Tartu
ZIP/Postal Code
50410
Country
Estonia
Facility Name
Novartis Investigative Site
City
Tampere
ZIP/Postal Code
33520
Country
Finland
Facility Name
Novartis Investigative Site
City
Montpellier cedex 5
State/Province
Herault
ZIP/Postal Code
34059
Country
France
Facility Name
Novartis Investigative Site
City
Paris
ZIP/Postal Code
75015
Country
France
Facility Name
Novartis Investigative Site
City
Dresden
State/Province
Sachsen
ZIP/Postal Code
01099
Country
Germany
Facility Name
Novartis Investigative Site
City
Bad Homburg
ZIP/Postal Code
61348
Country
Germany
Facility Name
Novartis Investigative Site
City
Bad Krozingen
ZIP/Postal Code
79189
Country
Germany
Facility Name
Novartis Investigative Site
City
Berlin-Buch
ZIP/Postal Code
13125
Country
Germany
Facility Name
Novartis Investigative Site
City
Berlin
ZIP/Postal Code
10369
Country
Germany
Facility Name
Novartis Investigative Site
City
Berlin
ZIP/Postal Code
13405
Country
Germany
Facility Name
Novartis Investigative Site
City
Dessau-Roßlau
ZIP/Postal Code
06846
Country
Germany
Facility Name
Novartis Investigative Site
City
Dresden
ZIP/Postal Code
01307
Country
Germany
Facility Name
Novartis Investigative Site
City
Dresden
ZIP/Postal Code
01309
Country
Germany
Facility Name
Novartis Investigative Site
City
Elsterwerda
ZIP/Postal Code
04910
Country
Germany
Facility Name
Novartis Investigative Site
City
Frankfurt
ZIP/Postal Code
60488
Country
Germany
Facility Name
Novartis Investigative Site
City
Frankfurt
ZIP/Postal Code
65929
Country
Germany
Facility Name
Novartis Investigative Site
City
Hamburg
ZIP/Postal Code
22291
Country
Germany
Facility Name
Novartis Investigative Site
City
Hamburg
ZIP/Postal Code
22765
Country
Germany
Facility Name
Novartis Investigative Site
City
Huy / OT Anderbeck
ZIP/Postal Code
38836
Country
Germany
Facility Name
Novartis Investigative Site
City
Ingelheim
ZIP/Postal Code
55218
Country
Germany
Facility Name
Novartis Investigative Site
City
Kelkheim
ZIP/Postal Code
65779
Country
Germany
Facility Name
Novartis Investigative Site
City
Koethen
ZIP/Postal Code
06366
Country
Germany
Facility Name
Novartis Investigative Site
City
Künzelsau
ZIP/Postal Code
74653
Country
Germany
Facility Name
Novartis Investigative Site
City
Leipzig
ZIP/Postal Code
04109
Country
Germany
Facility Name
Novartis Investigative Site
City
Leipzig
ZIP/Postal Code
04129
Country
Germany
Facility Name
Novartis Investigative Site
City
Leipzig
ZIP/Postal Code
04315
Country
Germany
Facility Name
Novartis Investigative Site
City
Loehne
ZIP/Postal Code
32584
Country
Germany
Facility Name
Novartis Investigative Site
City
Muehldorf
ZIP/Postal Code
84453
Country
Germany
Facility Name
Novartis Investigative Site
City
Muehlheim An Der Ruhr
ZIP/Postal Code
45468
Country
Germany
Facility Name
Novartis Investigative Site
City
Offenbach
ZIP/Postal Code
63073
Country
Germany
Facility Name
Novartis Investigative Site
City
Wermsdorf
ZIP/Postal Code
04779
Country
Germany
Facility Name
Novartis Investigative Site
City
Wetzlar-Naunheim
ZIP/Postal Code
35584
Country
Germany
Facility Name
Novartis Investigative Site
City
Weyhe
ZIP/Postal Code
28844
Country
Germany
Facility Name
Novartis Investigative Site
City
Guatemala
State/Province
Ciudad
ZIP/Postal Code
01010
Country
Guatemala
Facility Name
Novartis Investigative Site
City
Guatemala City
ZIP/Postal Code
01010
Country
Guatemala
Facility Name
Novartis Investigative Site
City
Guatemala City
ZIP/Postal Code
01015
Country
Guatemala
Facility Name
Novartis Investigative Site
City
Hong Kong SAR
Country
Hong Kong
Facility Name
Novartis Investigative Site
City
Hong Kong
ZIP/Postal Code
HONG KONG
Country
Hong Kong
Facility Name
Novartis Investigative Site
City
Budapest
ZIP/Postal Code
1096
Country
Hungary
Facility Name
Novartis Investigative Site
City
Budapest
ZIP/Postal Code
1122
Country
Hungary
Facility Name
Novartis Investigative Site
City
Budapest
ZIP/Postal Code
1125
Country
Hungary
Facility Name
Novartis Investigative Site
City
Budapest
ZIP/Postal Code
1134
Country
Hungary
Facility Name
Novartis Investigative Site
City
Budapest
ZIP/Postal Code
1145
Country
Hungary
Facility Name
Novartis Investigative Site
City
Debrecen
ZIP/Postal Code
4032
Country
Hungary
Facility Name
Novartis Investigative Site
City
Nyiregyháza
ZIP/Postal Code
4400
Country
Hungary
Facility Name
Novartis Investigative Site
City
Szekesfehervar
ZIP/Postal Code
H-8000
Country
Hungary
Facility Name
Novartis Investigative Site
City
Szekszard
ZIP/Postal Code
7100
Country
Hungary
Facility Name
Novartis Investigative Site
City
Zalaegerszeg
ZIP/Postal Code
8900
Country
Hungary
Facility Name
Novartis Investigative Site
City
Guntur
State/Province
Andhra Pradesh
ZIP/Postal Code
522001
Country
India
Facility Name
Novartis Investigative Site
City
Dehli
State/Province
Delhi
ZIP/Postal Code
110080
Country
India
Facility Name
Novartis Investigative Site
City
Ahmedabad
State/Province
Gujarat
ZIP/Postal Code
380 051
Country
India
Facility Name
Novartis Investigative Site
City
Ahmedabad
State/Province
Gujarat
ZIP/Postal Code
380054
Country
India
Facility Name
Novartis Investigative Site
City
Anand
State/Province
Gujarat
ZIP/Postal Code
388325
Country
India
Facility Name
Novartis Investigative Site
City
Surat
State/Province
Gujarat
ZIP/Postal Code
395 002
Country
India
Facility Name
Novartis Investigative Site
City
Surat
State/Province
Gujrat
ZIP/Postal Code
395002
Country
India
Facility Name
Novartis Investigative Site
City
Vadodara
State/Province
Gujrat
ZIP/Postal Code
390015
Country
India
Facility Name
Novartis Investigative Site
City
Mumbai
State/Province
Maharashtra
ZIP/Postal Code
400012
Country
India
Facility Name
Novartis Investigative Site
City
Nagpur
State/Province
Maharashtra
ZIP/Postal Code
400012
Country
India
Facility Name
Novartis Investigative Site
City
Nagpur
State/Province
Maharashtra
ZIP/Postal Code
440010
Country
India
Facility Name
Novartis Investigative Site
City
Nashik
State/Province
Maharashtra
ZIP/Postal Code
422 005
Country
India
Facility Name
Novartis Investigative Site
City
Nashik
State/Province
Maharashtra
ZIP/Postal Code
422002
Country
India
Facility Name
Novartis Investigative Site
City
Nashik
State/Province
Maharashtra
ZIP/Postal Code
422005
Country
India
Facility Name
Novartis Investigative Site
City
Pune
State/Province
Maharashtra
ZIP/Postal Code
411 011
Country
India
Facility Name
Novartis Investigative Site
City
Pune
State/Province
Maharashtra
ZIP/Postal Code
411011
Country
India
Facility Name
Novartis Investigative Site
City
Ludhiana
State/Province
Punjab
ZIP/Postal Code
141002
Country
India
Facility Name
Novartis Investigative Site
City
Bikaner
State/Province
Rajasthan
ZIP/Postal Code
334003
Country
India
Facility Name
Novartis Investigative Site
City
Hyderabad
State/Province
Telangana
ZIP/Postal Code
500 063
Country
India
Facility Name
Novartis Investigative Site
City
Indore
ZIP/Postal Code
452014
Country
India
Facility Name
Novartis Investigative Site
City
Ashkelon
ZIP/Postal Code
78278
Country
Israel
Facility Name
Novartis Investigative Site
City
Hadera
ZIP/Postal Code
38100
Country
Israel
Facility Name
Novartis Investigative Site
City
Haifa
ZIP/Postal Code
3436212
Country
Israel
Facility Name
Novartis Investigative Site
City
Haifa
ZIP/Postal Code
3525408
Country
Israel
Facility Name
Novartis Investigative Site
City
Jerusalem
ZIP/Postal Code
91120
Country
Israel
Facility Name
Novartis Investigative Site
City
Petach Tikva
ZIP/Postal Code
49100
Country
Israel
Facility Name
Novartis Investigative Site
City
Rehovot
ZIP/Postal Code
76100
Country
Israel
Facility Name
Novartis Investigative Site
City
Safed
ZIP/Postal Code
13100
Country
Israel
Facility Name
Novartis Investigative Site
City
Aosta
State/Province
AO
ZIP/Postal Code
11100
Country
Italy
Facility Name
Novartis Investigative Site
City
Cortona
State/Province
AR
ZIP/Postal Code
52044
Country
Italy
Facility Name
Novartis Investigative Site
City
Bergamo
State/Province
BG
ZIP/Postal Code
24127
Country
Italy
Facility Name
Novartis Investigative Site
City
Treviglio
State/Province
BG
ZIP/Postal Code
24047
Country
Italy
Facility Name
Novartis Investigative Site
City
Cosenza
State/Province
CS
ZIP/Postal Code
87100
Country
Italy
Facility Name
Novartis Investigative Site
City
Cona
State/Province
FE
ZIP/Postal Code
44100
Country
Italy
Facility Name
Novartis Investigative Site
City
Genova
State/Province
GE
ZIP/Postal Code
16132
Country
Italy
Facility Name
Novartis Investigative Site
City
Pozzilli
State/Province
IS
ZIP/Postal Code
86077
Country
Italy
Facility Name
Novartis Investigative Site
City
Lido di Camaiore
State/Province
LU
ZIP/Postal Code
55041
Country
Italy
Facility Name
Novartis Investigative Site
City
Milazzo
State/Province
ME
ZIP/Postal Code
98057
Country
Italy
Facility Name
Novartis Investigative Site
City
Pisa
State/Province
PI
ZIP/Postal Code
56126
Country
Italy
Facility Name
Novartis Investigative Site
City
Pescia
State/Province
Point
ZIP/Postal Code
51017
Country
Italy
Facility Name
Novartis Investigative Site
City
Pavia
State/Province
PV
ZIP/Postal Code
27100
Country
Italy
Facility Name
Novartis Investigative Site
City
Ariccia
State/Province
RM
ZIP/Postal Code
00041
Country
Italy
Facility Name
Novartis Investigative Site
City
Roma
State/Province
RM
ZIP/Postal Code
00163
Country
Italy
Facility Name
Novartis Investigative Site
City
Salerno
State/Province
SA
ZIP/Postal Code
84131
Country
Italy
Facility Name
Novartis Investigative Site
City
Sassari
State/Province
SS
ZIP/Postal Code
07100
Country
Italy
Facility Name
Novartis Investigative Site
City
Wonju
State/Province
Gangwon-Do
ZIP/Postal Code
26426
Country
Korea, Republic of
Facility Name
Novartis Investigative Site
City
Suwon
State/Province
Gyeonggi-do
ZIP/Postal Code
16499
Country
Korea, Republic of
Facility Name
Novartis Investigative Site
City
Seoul
State/Province
Korea
ZIP/Postal Code
05505
Country
Korea, Republic of
Facility Name
Novartis Investigative Site
City
Seoul
State/Province
Seocho-gu
ZIP/Postal Code
06591
Country
Korea, Republic of
Facility Name
Novartis Investigative Site
City
Daegu
ZIP/Postal Code
705 718
Country
Korea, Republic of
Facility Name
Novartis Investigative Site
City
Daegu
ZIP/Postal Code
705703
Country
Korea, Republic of
Facility Name
Novartis Investigative Site
City
Seoul
ZIP/Postal Code
05355
Country
Korea, Republic of
Facility Name
Novartis Investigative Site
City
Seoul
ZIP/Postal Code
156-707
Country
Korea, Republic of
Facility Name
Novartis Investigative Site
City
Daugavpils
ZIP/Postal Code
LV-5417
Country
Latvia
Facility Name
Novartis Investigative Site
City
Ventspils
ZIP/Postal Code
LV-3601
Country
Latvia
Facility Name
Novartis Investigative Site
City
Kaunas
ZIP/Postal Code
LT-49387
Country
Lithuania
Facility Name
Novartis Investigative Site
City
Kedainiai
ZIP/Postal Code
LT-57164
Country
Lithuania
Facility Name
Novartis Investigative Site
City
Vilnius
ZIP/Postal Code
LT-08661
Country
Lithuania
Facility Name
Novartis Investigative Site
City
Kuala Lumpur
ZIP/Postal Code
50400
Country
Malaysia
Facility Name
Novartis Investigative Site
City
Kuala Lumpur
ZIP/Postal Code
59100
Country
Malaysia
Facility Name
Novartis Investigative Site
City
San Juan del Rio
State/Province
Queretaro
ZIP/Postal Code
76800
Country
Mexico
Facility Name
Novartis Investigative Site
City
Aguascalientes
ZIP/Postal Code
20230
Country
Mexico
Facility Name
Novartis Investigative Site
City
San Luis Potosi
ZIP/Postal Code
78200
Country
Mexico
Facility Name
Novartis Investigative Site
City
San Luis Potosí
ZIP/Postal Code
78200
Country
Mexico
Facility Name
Novartis Investigative Site
City
Breda
State/Province
CK
ZIP/Postal Code
4818
Country
Netherlands
Facility Name
Novartis Investigative Site
City
Amersfoort
ZIP/Postal Code
3813 TZ
Country
Netherlands
Facility Name
Novartis Investigative Site
City
Arnhem
ZIP/Postal Code
6815 AD
Country
Netherlands
Facility Name
Novartis Investigative Site
City
Blaricum
ZIP/Postal Code
1261 AN
Country
Netherlands
Facility Name
Novartis Investigative Site
City
Delft
ZIP/Postal Code
2625 AD
Country
Netherlands
Facility Name
Novartis Investigative Site
City
Den Bosch
ZIP/Postal Code
5223 GZ
Country
Netherlands
Facility Name
Novartis Investigative Site
City
Ede
ZIP/Postal Code
6716 RP
Country
Netherlands
Facility Name
Novartis Investigative Site
City
Gorinchem
ZIP/Postal Code
4204 AA
Country
Netherlands
Facility Name
Novartis Investigative Site
City
Hardenberg
ZIP/Postal Code
7770 AA
Country
Netherlands
Facility Name
Novartis Investigative Site
City
Harderwijk
ZIP/Postal Code
3840 AC
Country
Netherlands
Facility Name
Novartis Investigative Site
City
Heerenveen
ZIP/Postal Code
8441 PW
Country
Netherlands
Facility Name
Novartis Investigative Site
City
Hengelo
ZIP/Postal Code
7555 DL
Country
Netherlands
Facility Name
Novartis Investigative Site
City
Sneek
ZIP/Postal Code
8601 ZK
Country
Netherlands
Facility Name
Novartis Investigative Site
City
Tilburg
ZIP/Postal Code
5022 GC
Country
Netherlands
Facility Name
Novartis Investigative Site
City
Veldhoven
ZIP/Postal Code
5504 DB
Country
Netherlands
Facility Name
Novartis Investigative Site
City
Panama City
ZIP/Postal Code
0816-02351
Country
Panama
Facility Name
Novartis Investigative Site
City
Panama City
Country
Panama
Facility Name
Novartis Investigative Site
City
Bellavista
State/Province
Lima
ZIP/Postal Code
CALLAO 02
Country
Peru
Facility Name
Novartis Investigative Site
City
Jesus Maria
State/Province
Lima
ZIP/Postal Code
11
Country
Peru
Facility Name
Novartis Investigative Site
City
La Molina
State/Province
Lima
ZIP/Postal Code
12
Country
Peru
Facility Name
Novartis Investigative Site
City
San Borja
State/Province
Lima
ZIP/Postal Code
41
Country
Peru
Facility Name
Novartis Investigative Site
City
San Isidro
State/Province
Lima
ZIP/Postal Code
27
Country
Peru
Facility Name
Novartis Investigative Site
City
San Miguel
State/Province
Lima
ZIP/Postal Code
32
Country
Peru
Facility Name
Novartis Investigative Site
City
Arequipa
ZIP/Postal Code
AREQ01
Country
Peru
Facility Name
Novartis Investigative Site
City
Lipa City
State/Province
Batangas
ZIP/Postal Code
4217
Country
Philippines
Facility Name
Novartis Investigative Site
City
Quezon City
State/Province
Manila
ZIP/Postal Code
1100
Country
Philippines
Facility Name
Novartis Investigative Site
City
Pasig City
ZIP/Postal Code
1605
Country
Philippines
Facility Name
Novartis Investigative Site
City
Quezon City
ZIP/Postal Code
1100
Country
Philippines
Facility Name
Novartis Investigative Site
City
Quezon City
ZIP/Postal Code
1102
Country
Philippines
Facility Name
Novartis Investigative Site
City
Gdynia
ZIP/Postal Code
81-472
Country
Poland
Facility Name
Novartis Investigative Site
City
Gdynia
ZIP/Postal Code
81-548
Country
Poland
Facility Name
Novartis Investigative Site
City
Lublin
ZIP/Postal Code
20-857
Country
Poland
Facility Name
Novartis Investigative Site
City
Vila Real
State/Province
Portuigal
ZIP/Postal Code
5000-508
Country
Portugal
Facility Name
Novartis Investigative Site
City
Covilha
ZIP/Postal Code
6200-251
Country
Portugal
Facility Name
Novartis Investigative Site
City
Guimaraes
ZIP/Postal Code
4835-044
Country
Portugal
Facility Name
Novartis Investigative Site
City
Lisboa
ZIP/Postal Code
1449-005
Country
Portugal
Facility Name
Novartis Investigative Site
City
Portalegre
ZIP/Postal Code
7300-853
Country
Portugal
Facility Name
Novartis Investigative Site
City
Porto
ZIP/Postal Code
4200-319
Country
Portugal
Facility Name
Novartis Investigative Site
City
Setubal
ZIP/Postal Code
2910-446
Country
Portugal
Facility Name
Novartis Investigative Site
City
Bucharest
State/Province
District 1
Country
Romania
Facility Name
Novartis Investigative Site
City
Bucuresti
State/Province
District 1
ZIP/Postal Code
014461
Country
Romania
Facility Name
Novartis Investigative Site
City
Craiova
State/Province
Jud. Dolj
ZIP/Postal Code
200497
Country
Romania
Facility Name
Novartis Investigative Site
City
Timisoara
State/Province
Timis
ZIP/Postal Code
300362
Country
Romania
Facility Name
Novartis Investigative Site
City
Bucharest
ZIP/Postal Code
050098
Country
Romania
Facility Name
Novartis Investigative Site
City
Bucuresti
ZIP/Postal Code
011728
Country
Romania
Facility Name
Novartis Investigative Site
City
Craiova
ZIP/Postal Code
200642
Country
Romania
Facility Name
Novartis Investigative Site
City
Deva
ZIP/Postal Code
330084
Country
Romania
Facility Name
Novartis Investigative Site
City
Timisoara
ZIP/Postal Code
300041
Country
Romania
Facility Name
Novartis Investigative Site
City
Timisoara
ZIP/Postal Code
300736
Country
Romania
Facility Name
Novartis Investigative Site
City
Ekaterinburg
ZIP/Postal Code
620137
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Ivanovo
ZIP/Postal Code
153012
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Kazan
ZIP/Postal Code
420012
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Kemerovo
ZIP/Postal Code
650002
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Kirov
ZIP/Postal Code
610027
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Krasnodar
ZIP/Postal Code
350012
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Moscow
ZIP/Postal Code
101990
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Moscow
ZIP/Postal Code
115280
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Moscow
ZIP/Postal Code
115516
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Moscow
ZIP/Postal Code
117198
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Moscow
ZIP/Postal Code
119881
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Moscow
ZIP/Postal Code
121309
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Moscow
ZIP/Postal Code
121552
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Moscow
ZIP/Postal Code
127473
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
N. Novgorod
ZIP/Postal Code
603003
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
N.Novgorod
ZIP/Postal Code
603005
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Nizhnii Novgorod
ZIP/Postal Code
603126
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Novosibirsk-117
ZIP/Postal Code
630117
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Orenburg
ZIP/Postal Code
460000
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Orenburg
ZIP/Postal Code
460040
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Perm
ZIP/Postal Code
614097
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Rostov-on-Don
ZIP/Postal Code
344022
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
S-Petersburg
ZIP/Postal Code
194354
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Saint Petersburg
ZIP/Postal Code
197022
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Saint Petersburg
ZIP/Postal Code
197341
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Saint Petersburg
ZIP/Postal Code
199106
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Saint-Petersburg
ZIP/Postal Code
191144
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Saint-Petersburg
ZIP/Postal Code
194044
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Saratov
ZIP/Postal Code
410012
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Smolensk
ZIP/Postal Code
214018
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
St-Petersburg
ZIP/Postal Code
194017
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
St-Petersburg
ZIP/Postal Code
194295
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
St-Petersburg
ZIP/Postal Code
196084
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Tula
ZIP/Postal Code
300053
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Vladimir
ZIP/Postal Code
600020
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Singapore
ZIP/Postal Code
169609
Country
Singapore
Facility Name
Novartis Investigative Site
City
Singapore
ZIP/Postal Code
308433
Country
Singapore
Facility Name
Novartis Investigative Site
City
Brezno
State/Province
Slovak Republic
ZIP/Postal Code
977 42
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Kosice
State/Province
Slovak Republic
ZIP/Postal Code
040 22
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Levice
State/Province
Slovak Republic
ZIP/Postal Code
93401
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Presov
State/Province
Slovak Republic
ZIP/Postal Code
08001
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Svidnik
State/Province
Slovak Republic
ZIP/Postal Code
08901
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Bratislava
ZIP/Postal Code
821 07
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Bratislava
ZIP/Postal Code
842 31
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Bratislava
ZIP/Postal Code
851 07
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Kosice
ZIP/Postal Code
040 01
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Lucenec
ZIP/Postal Code
984 01
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Martin
ZIP/Postal Code
036 01
Country
Slovakia
Facility Name
Novartis Investigative Site
City
Bloemfontein
State/Province
Free State
ZIP/Postal Code
9301
Country
South Africa
Facility Name
Novartis Investigative Site
City
Soweto
State/Province
Gauteng
ZIP/Postal Code
2013
Country
South Africa
Facility Name
Novartis Investigative Site
City
Durban
State/Province
Kwa-Zulu Natal
ZIP/Postal Code
4052
Country
South Africa
Facility Name
Novartis Investigative Site
City
Cape Town
State/Province
Western Cape
ZIP/Postal Code
7405
Country
South Africa
Facility Name
Novartis Investigative Site
City
Alberton
ZIP/Postal Code
1449
Country
South Africa
Facility Name
Novartis Investigative Site
City
Bloemfontein
ZIP/Postal Code
9301
Country
South Africa
Facility Name
Novartis Investigative Site
City
Cape Town
ZIP/Postal Code
7405
Country
South Africa
Facility Name
Novartis Investigative Site
City
Cape Town
ZIP/Postal Code
7505
Country
South Africa
Facility Name
Novartis Investigative Site
City
Durban
ZIP/Postal Code
4110
Country
South Africa
Facility Name
Novartis Investigative Site
City
Johannesburg
ZIP/Postal Code
2193
Country
South Africa
Facility Name
Novartis Investigative Site
City
Kempton Park
ZIP/Postal Code
1620
Country
South Africa
Facility Name
Novartis Investigative Site
City
Pretoria
ZIP/Postal Code
0121
Country
South Africa
Facility Name
Novartis Investigative Site
City
Pretoria
ZIP/Postal Code
0184
Country
South Africa
Facility Name
Novartis Investigative Site
City
Worcester
ZIP/Postal Code
6850
Country
South Africa
Facility Name
Novartis Investigative Site
City
Malaga
State/Province
Andalucia
ZIP/Postal Code
29010
Country
Spain
Facility Name
Novartis Investigative Site
City
Marbella
State/Province
Andalucia
ZIP/Postal Code
29600
Country
Spain
Facility Name
Novartis Investigative Site
City
Sevilla
State/Province
Andalucia
ZIP/Postal Code
41014
Country
Spain
Facility Name
Novartis Investigative Site
City
Sant Joan Despi
State/Province
Cataluna
ZIP/Postal Code
08970
Country
Spain
Facility Name
Novartis Investigative Site
City
Barcelona
State/Province
Catalunya
ZIP/Postal Code
08003
Country
Spain
Facility Name
Novartis Investigative Site
City
Barcelona
State/Province
Catalunya
ZIP/Postal Code
08035
Country
Spain
Facility Name
Novartis Investigative Site
City
Valencia
State/Province
Comunidad Valenciana
ZIP/Postal Code
46010
Country
Spain
Facility Name
Novartis Investigative Site
City
Valencia
State/Province
Comunidad Valenciana
ZIP/Postal Code
46015
Country
Spain
Facility Name
Novartis Investigative Site
City
A Coruna
State/Province
Galicia
ZIP/Postal Code
15006
Country
Spain
Facility Name
Novartis Investigative Site
City
La Coruna
State/Province
Galicia
ZIP/Postal Code
15006
Country
Spain
Facility Name
Novartis Investigative Site
City
Santiago de Compostela
State/Province
Galicia
ZIP/Postal Code
15706
Country
Spain
Facility Name
Novartis Investigative Site
City
Vigo
State/Province
Galicia
ZIP/Postal Code
36211
Country
Spain
Facility Name
Novartis Investigative Site
City
Alcala de Henares
State/Province
Madrid
ZIP/Postal Code
28805
Country
Spain
Facility Name
Novartis Investigative Site
City
Mostoles
State/Province
Madrid
ZIP/Postal Code
28935
Country
Spain
Facility Name
Novartis Investigative Site
City
Madrid
ZIP/Postal Code
28007
Country
Spain
Facility Name
Novartis Investigative Site
City
Madrid
ZIP/Postal Code
28222
Country
Spain
Facility Name
Novartis Investigative Site
City
Stockholm
State/Province
SE
ZIP/Postal Code
141 86
Country
Sweden
Facility Name
Novartis Investigative Site
City
Goteborg
ZIP/Postal Code
416 85
Country
Sweden
Facility Name
Novartis Investigative Site
City
Göteborg
ZIP/Postal Code
416 85
Country
Sweden
Facility Name
Novartis Investigative Site
City
Karlshamn
ZIP/Postal Code
37480
Country
Sweden
Facility Name
Novartis Investigative Site
City
Motala
ZIP/Postal Code
59185
Country
Sweden
Facility Name
Novartis Investigative Site
City
Changhua
ZIP/Postal Code
50006
Country
Taiwan
Facility Name
Novartis Investigative Site
City
Kaohsiung
ZIP/Postal Code
82445
Country
Taiwan
Facility Name
Novartis Investigative Site
City
Taichung
ZIP/Postal Code
40447
Country
Taiwan
Facility Name
Novartis Investigative Site
City
Taipei
ZIP/Postal Code
10002
Country
Taiwan
Facility Name
Novartis Investigative Site
City
Taipei
ZIP/Postal Code
11217
Country
Taiwan
Facility Name
Novartis Investigative Site
City
Taipei
ZIP/Postal Code
114
Country
Taiwan
Facility Name
Novartis Investigative Site
City
Yilan
ZIP/Postal Code
26058
Country
Taiwan
Facility Name
Novartis Investigative Site
City
Taladkwan
State/Province
Nonthaburi
ZIP/Postal Code
11000
Country
Thailand
Facility Name
Novartis Investigative Site
City
Khon Kaen
State/Province
THA
ZIP/Postal Code
40002
Country
Thailand
Facility Name
Novartis Investigative Site
City
Muang
ZIP/Postal Code
12120
Country
Thailand
Facility Name
Novartis Investigative Site
City
Istanbul
ZIP/Postal Code
34093
Country
Turkey
Facility Name
Novartis Investigative Site
City
Istanbul
ZIP/Postal Code
34304
Country
Turkey
Facility Name
Novartis Investigative Site
City
Izmir
ZIP/Postal Code
35040
Country
Turkey
Facility Name
Novartis Investigative Site
City
Izmir
ZIP/Postal Code
35340
Country
Turkey
Facility Name
Novartis Investigative Site
City
Kocaeli
ZIP/Postal Code
41380
Country
Turkey
Facility Name
Novartis Investigative Site
City
Sivas
ZIP/Postal Code
58140
Country
Turkey
Facility Name
Novartis Investigative Site
City
Durham
State/Province
County Durham
ZIP/Postal Code
DH1 5TW
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Dorchester
State/Province
Dorset
ZIP/Postal Code
DT1 2JY
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Basingstoke
State/Province
Hampshire
ZIP/Postal Code
RG24 9NA
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Portsmouth
State/Province
Hampshire
ZIP/Postal Code
PO6 3LY
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Inverness
State/Province
Invernesshire
ZIP/Postal Code
IV2 3RE
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Oldham
State/Province
Lancashire
ZIP/Postal Code
OL1 2JH
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Leicester
State/Province
Leicestershire
ZIP/Postal Code
LE2 7LX
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Craigavon
State/Province
Northern Ireland
ZIP/Postal Code
BT63 5QQ
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Dundee
State/Province
Perthshire
ZIP/Postal Code
DD1 9SY
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Taunton
State/Province
Somerset
ZIP/Postal Code
TA1 5DA
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Yeovil
State/Province
Somerset
ZIP/Postal Code
BA21 4AT
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Sheffield
State/Province
South Yorkshire
ZIP/Postal Code
S10 2JF
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Redhill
State/Province
Surrey
ZIP/Postal Code
RH1 5RH
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
South Shields
State/Province
Tyne And Wear
ZIP/Postal Code
NE34 0PL
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Sunderland
State/Province
Tyne And Wear
ZIP/Postal Code
SR4 7TP
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Dudley
State/Province
West Midlands
ZIP/Postal Code
DY1 2HQ
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Cheshire
ZIP/Postal Code
CW1 4QJ
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Coventry
ZIP/Postal Code
CV2 2DX
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Exeter
ZIP/Postal Code
EX2 5AX
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Kent
ZIP/Postal Code
DA2 8DA
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Manchester
ZIP/Postal Code
M13 9WL
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Milton Keynes
ZIP/Postal Code
MK6 5LD
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Newport
ZIP/Postal Code
NP20 2UB
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Newport
ZIP/Postal Code
P030 5TG
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Norwich
ZIP/Postal Code
NR4 7UY
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Poole
ZIP/Postal Code
BH15 2JB
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Rotherham
ZIP/Postal Code
S60 2OD
Country
United Kingdom
Facility Name
Novartis Investigative Site
City
Worcester
ZIP/Postal Code
WR5 1DD
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
Undecided
IPD Sharing Plan Description
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Learn more about this trial

Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction

We'll reach out to this number within 24 hrs